| 03.11.2025 16:00 | AZN | Result of General Meeting | RNS |
| 03.11.2025 15:00 | AZN | Total Voting Rights | RNS |
| 31.10.2025 10:08 | AZN | AstraZeneca hails phase 3 gefurulimab results in myasthenia gravis | Alliance |
| 30.10.2025 16:16 | TBCG, VTY, WPM | UK earnings, trading statements calendar - next 7 days | Alliance |
| 28.10.2025 09:36 | AZN | AstraZeneca hails EU approval of Koselugo for form of neurofibromas | Alliance |
| 28.10.2025 07:05 | AZN | Director Declaration | RNS |
| 28.10.2025 07:00 | AZN | Koselugo (selumetinib) approved in the EU | RNS |
| 27.10.2025 14:26 | AZN, TET, PHLL | UK shareholder meetings calendar - next 7 days | Alliance |
| 27.10.2025 09:45 | BHP, MACF, FRMI | LONDON BROKER RATINGS: Jefferies raises GSK and AstraZeneca to 'buy' | Alliance |
| 22.10.2025 09:53 | AZN | AstraZeneca hails EU approval of Tezspire for rhinosinusitis form | Alliance |
| 22.10.2025 09:42 | SHI, XPP, WOSG | LONDON BROKER RATINGS: Goldman raises IAG; Peel Hunt raises XP Power | Alliance |
| 22.10.2025 07:00 | AZN | Tezspire Approved in EU for CRSwNP | RNS |
| 20.10.2025 08:49 | AZN | AstraZeneca hails US FDA approval for Tezspire for rhinosinusitis form | Alliance |
| 20.10.2025 07:05 | AZN | US FDA Approves Tezspire in CRSwNP | RNS |
| 20.10.2025 07:00 | AZN | Positive CHMP opinion for subcutaneous Saphnelo | RNS |
| 17.10.2025 21:44 | AZN | Amgen and AstraZeneca says US FDA broadens indication for Tezspire | Alliance |
| 17.10.2025 20:08 | AZN | AstraZeneca's Saphnelo gets nod in EU for systemic lupus erythematosus | Alliance |
| 17.10.2025 14:02 | AZN | AstraZeneca says Imfinizi lowers mortality risk in bladder cancer | Alliance |
| 16.10.2025 09:35 | AZN, ENT, CNA | LONDON BROKER RATINGS: AstraZeneca cut; Barclays raises Centrica | Alliance |
| 13.10.2025 09:35 | AZN | UPDATE: AstraZeneca confirms deal with US government on drug prices | Alliance |
| 13.10.2025 07:09 | AZN | Trump announces deal with AstraZeneca on drug prices, tariffs | Alliance |
| 13.10.2025 07:00 | AZN | Agreement with US Govt to lower medicine prices | RNS |
| 10.10.2025 20:48 | AZN | PRESS: Trump strikes drug-pricing deal with AstraZeneca - MSNBC | Alliance |
| 09.10.2025 18:02 | AZN | AstraZeneca ups investment at new Virginia facility to USD4.5 billion | Alliance |
| 07.10.2025 08:40 | AZN | AstraZeneca touts positive results in trial for hypertension therapy | Alliance |
| 07.10.2025 07:00 | AZN | Baxdrostat met primary endpoint in Bax24 Ph3 trial | RNS |
| 06.10.2025 10:52 | AZN | PRESS: AstraZeneca signs USD555 million AI gene-editing deal – FT | Alliance |
| 06.10.2025 08:19 | AZN | AstraZeneca, Daiichi drug boosts survival in aggressive breast cancer | Alliance |
| 06.10.2025 07:30 | AZN | Datroway improved OS and PFS in TROPION-Breast02 | RNS |
| 02.10.2025 09:49 | CRH, CAML, JSE | LONDON BROKER RATINGS: UBS raises 3i Group; Exane BNP cuts BT | Alliance |
| 01.10.2025 16:59 | AZN | Daiichi and AstraZeneca's breast cancer therapy accepted for US review | Alliance |
| 01.10.2025 15:00 | AZN | Total Voting Rights | RNS |
| 01.10.2025 08:56 | AZN, GSK, CTEC | ConvaTec to open new research & development hub in Manchester | Alliance |
| 29.09.2025 09:17 | AZN | AstraZeneca to upgrade US listing but retain London base | Alliance |
| 29.09.2025 09:09 | HLN, GSK, AZN | GSK commercial chief to become CEO at start of "pivotal" 2026 | Alliance |
| 29.09.2025 07:30 | AZN | Enhertu improved IDFS in early BC in DB-05 | RNS |
| 29.09.2025 07:00 | AZN | AZN harmonises listing structure | RNS |
| 25.09.2025 16:30 | AZN | Director/PDMR Shareholding | RNS |
| 24.09.2025 10:55 | AZN | AstraZeneca and Daiichi's breast cancer drug wins US priority review | Alliance |
| 22.09.2025 08:39 | AZN | AstraZeneca says Tezspire and Koselugo recommended for approval in EU | Alliance |
| 22.09.2025 07:05 | AZN | Koselugo recommended for EU approval | RNS |
| 22.09.2025 07:00 | AZN | Tezspire Recommended for Approval in EU for CRSwNP | RNS |
| 19.09.2025 08:24 | AZN | AstraZeneca says Ultomiris shows 3 years relapse-free in NMOSD | Alliance |
| 17.09.2025 09:47 | STEM, GFRD, BME | LONDON BROKER RATINGS: Deutsche Bank Research cuts Eurowag to 'hold' | Alliance |
| 17.09.2025 09:06 | AZN | AstraZeneca lupus drug succeeds in trial as COPD therapy fails | Alliance |
| 17.09.2025 07:05 | AZN | Saphnelo met primary endpoint in TULIP-SC | RNS |
| 17.09.2025 07:00 | AZN | Update on RESOLUTE Phase III trial | RNS |
| 17.09.2025 06:49 | AZN, GSK | UK and US strike tech deal as Trump arrives for state visit | Alliance |
| 11.09.2025 10:11 | AZN | Daiichi Sankyo advances EU application for tumour agnostic Enhertu | Alliance |
| 01.09.2025 15:00 | AZN | Total Voting Rights | RNS |
| 01.09.2025 12:28 | VAL, VALT, BMS | UK dividends calendar - next 7 days | Alliance |
| 01.09.2025 06:50 | AZN | AstraZeneca celebrates baxdrostat trial results in hypertension form | Alliance |
| 28.08.2025 15:00 | AZN | Holding(s) in Company | RNS |
| 26.08.2025 15:00 | AZN | Holding(s) in Company | RNS |
| 21.08.2025 15:00 | AZN | Holding(s) in Company | RNS |
| 18.08.2025 15:00 | AZN | Director/PDMR Shareholding | RNS |
| 15.08.2025 15:00 | AZN | Holding(s) in Company | RNS |
| 13.08.2025 12:53 | SHEL, ULVR, AZN | PRESS: Rolls-Royce CEO rules out US listing amid high hopes for SMRs | Alliance |
| 12.08.2025 15:00 | AZN | Holding(s) in Company | RNS |
| 04.08.2025 09:37 | DEBS, ITM, SEPL | LONDON BROKER RATINGS: Jefferies lifts BAE Systems; HSBC cuts Shell | Alliance |
| 01.08.2025 15:00 | AZN | Total Voting Rights | RNS |
| 31.07.2025 14:24 | SGRO, STAN, NICL | UK dividends calendar - next 7 days | Alliance |
| 31.07.2025 10:05 | CRE, RHIM, ABDN | LONDON BROKER RATINGS: Deutsche cuts Rio Tinto; Kepler raises Unite | Alliance |
| 30.07.2025 10:10 | FORT, CWR, FXPO | LONDON BROKER RATINGS: JPMorgan raises Croda; Peel Hunt cuts Ferrexpo | Alliance |
| 29.07.2025 08:56 | AZN | AstraZeneca second quarter sales and profit boosted by cancer drugs | Alliance |
| 29.07.2025 07:00 | AZN | H1 and Q2 2025 results | RNS |
| 28.07.2025 08:25 | AZN | AstraZeneca's Imfinzi granted priority review for cancer forms in US | Alliance |
| 25.07.2025 12:15 | AZN | AstraZeneca receives positive opinion from EMA for COPD therapy | Alliance |
| 24.07.2025 14:10 | AZN | AstraZeneca hails gefurulimab trial results on myasthenia gravis | Alliance |
| 24.07.2025 07:00 | AZN | Gefurulimab nanobody met Phase III endpoints | RNS |
| 22.07.2025 13:44 | UTG, TSTL, SHC | UK earnings, trading statements calendar - next 7 days | Alliance |
| 22.07.2025 07:00 | AZN | AstraZeneca plans to invest $50bn in the US | RNS |
| 21.07.2025 16:34 | AZN | CORRECT: AstraZeneca hails "meaningful" results in cancer drug trial | Alliance |
| 21.07.2025 08:34 | AZN | AstraZeneca hails "meaningful" results in cancer drug trial | Alliance |
| 16.07.2025 09:02 | AZN | AstraZeneca rare disease antibody shy of main goal in trial | Alliance |
